Brain substates induced by DMT relate to sympathetic output and meaningfulness of the experience
Using simultaneous fMRI and EKG in 14 volunteers, the study identifies a DMT‑induced brain substate—hippocampal and medial parietal deactivation with increased superior temporal activity—linked to altered sense of time/space/self and vivid audio‑visual “entities”. Increased heart rate covaried with these deactivations and the experience of entities, suggesting a chain from sympathetic activation to specific neural and phenomenological effects that may relate to therapeutic changes in self‑referential processing.
Authors
- Robin Carhart-Harris
- Christopher Timmermann
- Leor Roseman
Published
Abstract
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic, known to rapidly induce short-lasting alterations in conscious experience, characterized by a profound and immersive sense of physical transcendence alongside rich and vivid auditory distortions and visual imagery. Multimodal neuroimaging data paired with dynamic analysis techniques offer a valuable approach for identifying unique signatures of brain activity – and linked autonomic physiology – naturally unfolding during the altered state of consciousness induced by DMT. We leveraged simultaneous fMRI and EKG data acquired in 14 healthy volunteers prior to, during, and after intravenous administration of DMT, and, separately, placebo. fMRI data was preprocessed to derive individual dynamic activity matrices, reflecting the similarity of brain activity in time, and community detection algorithms were applied on these matrices to identify brain activity substates; EKG data was used to derive continuous heart rate. We identified a brain substate occurring immediately after DMT injection, characterized by hippocampal and medial parietal deactivations and increased superior temporal lobe activity under DMT. Deactivations in the hippocampus and medial parietal cortex correlated with alterations in the usual sense of time, space and self-referential processes, reflecting a deconstruction of essential features of ordinary consciousness. Superior lobe activations instead correlated with audio/visual hallucinations and experience of “ entities ”, reflecting the emergence of altered sensory experiences under DMT. Finally, increased heart rate under DMT correlated positively with hippocampus/medial parietal deactivation and the experience of “ entities ”, and negatively with altered self-referential processes. These results suggest a chain of influence linking sympathetic regulation to hippocampal and medial parietal deactivations under DMT, which combined, may contribute to positive mental health outcomes related to self-referential processing following psychedelic administration.
Research Summary of 'Brain substates induced by DMT relate to sympathetic output and meaningfulness of the experience'
Introduction
Pasquini and colleagues situate this study in the context of two complementary aspects of selfhood: a bodily or interoceptive self that depends on integration of autonomic and visceral signals, and a narrative self that depends on medial temporal and midline parietal structures associated with autobiographical memory and self-referential thought (the default mode network, DMN). They note that serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) produce a rapid, short-lasting but intense alteration of consciousness with pronounced sensory immersion and changes in autonomic physiology, particularly transient increases in sympathetic tone measured via heart rate. Earlier neuroimaging studies of psychedelics have reported global connectivity changes and DMN disruptions, but the authors argue that the fast dynamics of intravenous DMT make it a useful probe for studying temporally evolving brain states and linked peripheral physiology using dynamic analysis methods applied to simultaneous fMRI and electrocardiogram (EKG) recordings. The study therefore aims to identify time-resolved brain activity ‘‘substates’’ that differentiate DMT from placebo and to link those substates to autonomic indices and subjective reports. Specifically, the investigators apply dynamic similarity-matrix analyses and graph-theoretical community detection to resting-state fMRI acquired with concurrent EKG in a within-subject, placebo-controlled design, to characterise the natural progression of neural and cardiac signatures unfolding immediately before, during, and after intravenous DMT administration. The goal is to test whether distinct substates arise under DMT, how long they persist, and whether substate-specific regional activations or deactivations relate to auditory distortions, ego-dissolution, meaningfulness of the experience, and heart-rate changes.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Pasquini, L., Simon, A. J., Gallen, C. L., Kettner, H., Roseman, L., Gazzaley, A., Carhart-Harris, R. L., & Timmermann, C. (2024). Brain substates induced by DMT relate to sympathetic output and meaningfulness of the experience. https://doi.org/10.1101/2024.02.14.580356
References (25)
Papers cited by this study that are also in Blossom
Alamia, A., Timmermann, C., Carhart-Harris, R. L. · eLife (2020)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Lawrence, D. W., Carhart-Harris, R. L., Griffiths, R. R. et al. · Research Square (2022)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Show all 25 referencesShow fewer
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Rosas, F. E., Mediano, P. A. M., Timmermann, C. et al. · Biorxiv (2023)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Nicol, G. E. · Nature (2024)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Vogt, S. B., Ley, L., Erne, L. et al. · Translational Psychiatry (2023)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Cited By (1)
Papers in Blossom that reference this study
Lima, G., Soares, C., Teixeira, M. et al. · Scientific Reports (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.